Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 0.66 |
| ▸ | KDR | P35968 | 6/20 | 0.66 |
| ▸ | RET | P07949 | 4/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.66 |
| ▸ | ABL1 | P00519 | 3/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.66 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.66 |
| ▸ | BRAF | P15056 | 3/20 | 0.66 |
| ▸ | PLK4 | O00444 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 2/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.66 |
| ▸ | LCK | P06239 | 2/20 | 0.66 |
| ▸ | FYN | P06241 | 2/20 | 0.66 |
| ▸ | LYN | P07948 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.66 |
| ▸ | AXL | P30530 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481171 | 0.95 | RAF1 (0.65) | RAF1KDRRETMAPK14EPHX2 | |
| SCHEMBL10324287 | 0.93 | RAF1 (0.75) | RAF1KDRRETMAPK14EPHX2 | |
| SCHEMBL14481178 | 0.90 | RAF1 (0.71) | RAF1KDRRETMAPK14EPHX2 | |
| SCHEMBL14751419 | 0.90 | KDR (0.70) | RAF1KDRRETMAPK14EPHX2 | |
| SCHEMBL13946016 | 0.87 | RAF1 (0.61) | RAF1KDRRETMAPK14EPHX2 | |
| Cm-4307 SCHEMBL14480690 | 0.87 | RAF1 (0.88) | RAF1KDRRETMAPK14EPHX2 | |
| Cm-4307 SCHEMBL29362075 | 0.87 | RAF1 (0.88) | RAF1KDRRETMAPK14EPHX2 | |
| Cm-4307 SCHEMBL30172564 | 0.87 | RAF1 (0.88) | RAF1KDRRETMAPK14EPHX2 | |
| SCHEMBL14680564 | 0.86 | RAF1 (0.60) | RAF1KDRRETMAPK14EPHX2 | |
| SCHEMBL17547702 | 0.86 | RAF1 (0.63) | RAF1KDRRETMAPK14EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088311-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-03-27 | — | — | US | disclosed |
| US-8669369-B2 | Method and process for preparation and production of deuterated Ω-diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-03-11 | — | — | US | disclosed |
| US-20130060044-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-03-07 | — | — | US | disclosed |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. | 2013-02-07 | — | — | US | disclosed |
| US-20130018209-A1 | PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-01-17 | — | — | US | disclosed |
| US-20130012548-A1 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088311-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | NMUR1, NMUR2, NUDT1 | RAF1 4326/4885KDR 4744/4885RET 3322/4885 |
| US-20130012548-A1 | DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | PPARD, HDHD5, SCD | RAF1 2908/4885KDR 1916/4885RET 2868/4885 |
| US-20130035492-A1 | METHOD AND PROCESS FOR PREPARATION AND PRODUCTION OF DEUTERATED OMEGA-DIPHENYLUREA | PNLIP, PDXK, PNP | RAF1 1962/4885KDR 3367/4885RET 3120/4885 |
| US-20130018209-A1 | PREPARATION METHODS OF METHYL-D3-AMINE AND SALTS THEREOF | NSD3, CCND3, DRD3 | RAF1 4408/4885KDR 4053/4885RET 2176/4885 |
| US-20130060044-A1 | METHOD FOR PREPARING DEUTERATED DIPHENYLUREA | NMUR1, NMUR2, NUDT1 | RAF1 4326/4885KDR 4744/4885RET 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.